"
[HTML] Fighting fibrosis
M Senior - Nature Biotechnology
… Two recent sets of positive clinical data have bucked the trend in the failure-strewn
idiopathic pulmonary fibrosis (IPF) field: BI’s phase 2 data for phosphodiesterase 4B
(PDE4B) inhibitor BI 1015550 in May 2022 and and Pliant Therapeutics’ phase 2a …
線維症との戦い
標的の選択性を改善し、細胞の表現型を定義することで、線維症の治療法を見つける可能性が高まる可能性がある。
Selected clinical IPF candidates
Compound/company |
Stage of development |
Mechanism of action |
Zinpentraxin alfa/Roche (previously Promedior) |
Phase 3 |
Recombinant human pentraxin-2; regulates immune cell–ECM interaction |
Pamrevlumab/Fibrogen |
Phase 3 |
Targets CTGF, involved in tissue remodeling and ECM synthesis |
BI 1015550/Boehringer Ingelheim |
Phase 3 (not yet recruiting) |
PDE4B inhibitor with anti-inflammatory effect; may have direct antifibrotic effect through TGFβ and CTGF |
Inhaled treprostinil (sold already as Tyvaso for PAH)/United Therapeutics |
Phase 3 |
Analog of prostacyclin, which has anti-inflammatory properties in the lung but can be pro-inflammatory elsewhere. |
GB0139/Galecto |
Phase 2b |
Inhibits galectin-3, expressed on inflammatory and fibrotic cell types and acts as a multifunctional signaling molecule |
PLN-74809/Pliant |
Phase 2a |
Inhibits integrins αvβ1 and αvβ6, found in fibrosis-linked fibroblasts and epithelial cells. |
BMS986278/Bristol Myers Squibb |
Phase 2 |
Inhibits the LPA1 receptor found on multiple fibrosis-implicated cell types |
HZN-825/Horizon Therapeutics |
Phase 2b |
Inhibits LPA receptor 1 |
Taladegib/Endeavor Biomedicines |
Phase 2 |
Small-molecule hedgehog signaling inhibitor |
Cudetaxestat/Blade Therapeutics |
Phase 1b/2 |
Allosteric inhibitor of autotaxin |
CTGF, connective tissue growth factor; ECM, extracellular matrix; LPA, lysophosphatidic acid; PDE4B, phosphodiesterase 4B; TGFβ, transforming growth factor β.
"
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。Googleが一定の重み付けはしているとは思いますが、玉石混交です。
癒しの音楽をお届けしています。
###